![]() ![]() By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. For further information, please contact or visit Reach is a non-regulatory news service. Terms and conditions relating to the use and distribution of this information may apply. ![]() This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Midatech' s headquarters and R&D facility is in Cardiff, UK. Midatech' s technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).All of the Company' s technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform: The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients. Midatech Pharma PLC (dual listed on LSE AIM: MTPH and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. ![]() IFC Advisory Limited (Financial PR and UK Investor Relations) If you would like to attend, you can register here for the event using code SHVIP for 75% off tickets. The Company will be attending MelloMonday on Monday 13 December 2021 taking place from 5.00pm to 9.30pm GMT. Stephen Stamp, Midatech' s CEO and CFO, will be presenting and taking questions from participants. Midatech Pharma PLC (AIM: MTPH Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce it is presenting at MelloMonday on Monday 13 December 2021, via a Zoom Webinar. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |